LCM
BPMC

Legato Capital Management’s Blueprint Medicines BPMC Stock Holding History

Legato Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,165
Closed -$557K – 574
2024
Q2 		$557K Buy
+5,165
New +$517K 0.08% 414

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Legato Capital Management's BPMC Position: Q3 2024 in Review

Legato Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 5,165 shares — an estimated $557K sold.

Legato Capital Management first reported a position in BPMC in Q2 2024 and held it in 1 quarter. The position peaked at $557K in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Legato Capital Management reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Legato Capital Management sold 5,165 Blueprint Medicines shares in Q3 2024, an estimated $557K.
  • Legato Capital Management first reported a position in Blueprint Medicines in Q2 2024 and held it in 1 quarter.
  • Legato Capital Management's Blueprint Medicines position peaked at $557K in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Legato Capital Management's 13F filing for Q3 2024, filed 7 Nov 2024.